Ari Nowacek, M.D, Ph.D. is a Principal with ARCH Venture Partners, joining the company as an Analyst in March 2015. Dr. Nowacek focuses on identifying and evaluating new life sciences technologies and also provides operating assistance to early-stage portfolio companies. He was instrumental in the development of ROME Therapeutics and Walden Biosciences. Dr. Nowacek is a physician-scientist by training with over 20 peer-reviewed publications and greater than 400 citations in the areas of neuroscience, virology, and antiretroviral therapeutic development. His research has led to 3 issued and 2 pending patents for therapeutic and R&D applications.
He holds a B.S. in Biology and a B.S. in Psychology from the University of Indiana-Bloomington where he graduated Magna Cum Laude and was elected to Phi Beta Kappa. He also holds an M.D. and Ph.D. from the University of Nebraska Medical Center and an M.B.A. from the University of Nebraska-Omaha. He subsequently completed a medical residency in pathology and post-doctoral research at The University of Chicago and Massachusetts General Hospital.